News
6h
TipRanks on MSNKlotho Neurosciences Receives FDA Orphan Drug DesignationKlotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...
Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...
US Stocks Likely To Open Lower A Day After Nasdaq Hits Record High: Nvidia, Kellogg, Klotho In Focus
U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...
Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...
Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process ...
Explore more
14h
InvestorsHub on MSNKlotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS TherapyShares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...
Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...
Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company’s investigations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results